Sanofi's Form 4 filing
Latigo Biotherapeutics, Inc. (LTGO) · filed Aug 12, 2026
- Accession no.
- 0001193125-26-345826
- Filed
- Aug 12, 2026, 8:18 AM ET
- Trade date
- Aug 10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| SanofiCIK 0001121404 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F2
The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
Remarks
Immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock. The convertibility and expiration of the Preferred Stock and Note prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 12, 2026.